

May 23, 2026

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051
NSE Symbol: PANACEABIO

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001
BSE Scrip Code: 531349

Reg.: Board Meeting on May 29, 2026, to approve Standalone and Consolidated Audited Financial Results for Quarter and Financial Year ended March 31, 2026

Dear Sir / Madam,

Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), this is to inform you that:

- (i) a meeting of the Board of Directors of the Company is scheduled to be held on Friday, May 29, 2026, at New Delhi, inter-alia, to consider and approve the Audited Financial Results for the Quarter and Financial Year ended March 31, 2026;
- (ii) in the said meeting, the Board may also consider the matter relating to recommendation / passing over of dividend on equity as well as preference shares for the said Financial Year;
- (iii) pursuant to Regulation 46(2) of the SEBI LODR Regulations, notice of the said meeting is also being uploaded on the website of the Company;
- (iv) with reference to our earlier announcement dated March 24, 2026 intimating the Closure of Trading Window pursuant to the Company's Code of Conduct for Prevention of Insider Trading framed in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, the trading window of the Company shall remain closed for all Designated Persons (including their Immediate Relatives) of the Company from April 01, 2026 till May 31, 2026 and the same will re-open from June 01, 2026.

This is for your kind information and record please.

Thanking you,

Sincerely yours,

For **Panacea Biotec Limited**

Ankit Jain
General Manager - Legal and Company Secretary